Rocketing demand for the weight loss benefits of semaglutide, fuelled by social media influencers, has caused a worldwide shortage of the diabetes medication.

In Australia, the manufacturer, Novo Nordisk, confirms the shortage will last until the end of the year. 

It has been exacerbated by extensive off-label prescribing for obesity, with the TGA recently warning doctors to prioritise access for patients with diabetes: the PBS-approved indication. 

Obesity specialist Professor Joseph Proietto — chair of the Clinical Care Committee of World Obesity — says affordability is a big issue for patients, with alternative therapies costing up to three times as much.